Gilead Sciences, Inc. v. Idenix Pharmaceuticals Inc.

Gilead Sciences, Inc. v. Idenix Pharmaceuticals Inc.

The Court held the '191 Patent invalid and void because at filing/publish date the patentees had no sound prediction of utility for 2'-C-Me/F compounds (factual basis and sound line of reasoning insufficient) and the specification failed to enable the essential fluorination step to make the claimed compounds (insufficient disclosure/undue experimentation); as a result Idenix's counterclaim was dismissed.

Citation
2015 FC 1156
Parties
Plaintiff: Gilead Sciences, Inc.; Plaintiff: Gilead Sciences Canada, Inc.; Defendant to the Counterclaim: Gilead Pharmasset LLC; Defendant; Plaintiff to the Counterclaim: Idenix Pharmaceuticals, Inc.; Defendant; Third Party to the Counterclaim: Universita Degli Studi Di Cagliari; Defendant; Third Party to the Counterclaim: L'Université Montpellier II; Defendant; Third Party to the Counterclaim: Centre National de la Recherche Scientifique
Court
Federal Court
Jurisdiction
Canada
Judgment Date
2 November 2015
Procedural Posture
Patent Infringement and Validity / Trial Judgment (federal Court)
Outcome
Declared Canadian Patent No. 2,490,191 invalid and void; Idenix counterclaim dismissed; costs awarded to Gilead
Legal Topics
Utility and Sound Prediction, Sufficiency of Disclosure (enablement), Anticipation, Inventorship (s.53), Infringement, Claim Construction, Overbreadth, Prodrug/metabolism
Source Language
English
Patent Law Intellectual Property Pharmaceuticals Biotechnology Civil Litigation Utility and Sound Prediction Sufficiency of Disclosure (enablement) Anticipation +5 more

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Legal principles 6 Authorities cited 9 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Gilead Sciences, Inc.

Plaintiff

Gilead Sciences Canada, Inc.

Plaintiff

Gilead Pharmasset LLC

Defendant to the Counterclaim

Idenix Pharmaceuticals, Inc.

Defendant; Plaintiff to the Counterclaim

Universita Degli Studi Di Cagliari

Defendant; Third Party to the Counterclaim

L'Université Montpellier II

Defendant; Third Party to the Counterclaim

Centre National de la Recherche Scientifique

Defendant; Third Party to the Counterclaim

Procedural Posture

Patent Infringement and Validity / Trial Judgment (federal Court)

Legal Issues

  1. 1 Whether Canadian Patent No. 2,490,191 is invalid for lack of utility (no sound prediction)
  2. 2 Whether the '191 Patent insufficiently discloses how to make the claimed 2'-C-Me/F compounds (enablement)
  3. 3 Whether the '191 Patent is overbroad

Ratio Decidendi

The Court held the '191 Patent invalid and void because at filing/publish date the patentees had no sound prediction of utility for 2'-C-Me/F compounds (factual basis and sound line of reasoning insufficient) and the specification failed to enable the essential fluorination step to make the claimed compounds (insufficient disclosure/undue experimentation); as a result Idenix's counterclaim was dismissed.

Court Disposition

Declared Canadian Patent No. 2,490,191 invalid and void; Idenix counterclaim dismissed; costs awarded to Gilead

Orders

  • Declaration that Canadian Patent No. 2,490,191 is invalid, void and of no force or effect
  • Dismissal of Idenix Pharmaceuticals, Inc.'s counterclaim in its entirety